- What This Report Will Provide?
- Expected Revenue Growth.
- Major Growth Boosters.
What This Report Will Provide?
This study involved four major activities in estimating the current size of the anatomic pathology market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.
Expected Revenue Growth:
[306 Pages Report] The global anatomic pathology market size is estimated to grow from USD 33.3 billion in 2020 to USD 46.8 billion by 2025, at a CAGR of 7.1%.
The growth in this market is majorly driven by the high incidence of cancer and other target diseases, availability of reimbursement, and the growing focus on personalized medicine. However, the availability of refurbished products, the lack of skilled professionals, and product recalls are expected to hamper the market growth to a certain extent during the forecast period.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=137323145
COVID-19 Impact on Anatomic Pathology Market
Globally, the COVID-19 outbreak has impacted every aspect of the diagnostics industry, including the anatomic pathology market. In the last few months, the number of patient visits to hospitals has reduced significantly, despite emergency and OPD services being available in hospitals.
After commencing cancer surgeries or other surgeries, surgeons run through a series of pathology tests to decide the best treatment for patients. However, due to the lockdown in Q2 of many countries, elective and cancer surgeries have reduced significantly. For instance, according to the World Economic Forum, 28 million elective surgeries and 38% of global cancer surgeries have been delayed or postponed in Q2. As a result, the number of diagnostic tests has reduced. This has further reduced the sales of anatomic pathology products during the Q2 2020. Moreover, due to the robust increase in the incidence of COVID- 19, pathology laboratories are now prioritizing and focusing on COVID-19 tests.
- In March 2020, Sakura Finetek Launched four new ready-to-use antibodies for the Tissue-Tek Genie Advanced Staining System
- In September 2018, Sakura Finetek launched the Accu-Cut SRM 300 LT Manual Microtome.
- In 2018, F. Hoffmann-La Roche received the CE approval for its BenchMark ULTRA Plus Staining System.
- In March 2016, BD received FDA approval for its new automated cervical cancer screening systems, BD Totalys MultiProcessor and BD Totalys SlidePrep instruments
Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=137323145
High incidence of cancer and other targeted diseases
Cancer is a complex disease that develops through the multi-stage carcinogenesis process involving multiple pathways. As a result, there are various hurdles associated with cancer diagnosis, prognosis, and therapy. Histopathology is the microscopic study of diseased tissue. It is a vital part of anatomic pathology since the accurate diagnosis of cancer and other diseases usually requires the histopathological examination of samples. This is an important indicator of market growth due to the rising prevalence and incidence of cancer globally.
Regional Growth Analysis:
Based on the region, the global anatomic pathology market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. In 2019, North America accounted for the largest market share, followed by Europe. The easy accessibility to advanced technologies, government initiatives for screening cancer patients, favorable reimbursement scenario for anatomic pathology diagnostic tests, increasing healthcare expenditure, and the presence of high-quality infrastructure for hospitals and clinical laboratories in the region are the major factors driving the growth of the anatomic pathology market in North America.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.